Fusion protein based on Grb2-SH2 domain for cancer therapy

Biochemical and Biophysical Research Communications

Volumn 399, Issue 2, 2010, Pages 262-267

  Saito, Yuriko ^a,c,d   Furukawa, Takako ^a,b   Arano, Yasushi ^c   Fujibayashi, Yasuhisa ^a,b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer therapy; EGFR; Grb2; SH2 domain

Indexed keywords

GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P42; PROTEIN SH2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GRB2 ADAPTOR PROTEIN; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SRC HOMOLOGY DOMAINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955844355     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.066     Document Type: Article

References (30)

1. Wiley H.S. Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell Res. 2003, 284:78-88.
2. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 2004, 319:1-11.
3. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
4. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33:369-385.
5. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
6. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995, 55:3140-3148.
7. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7:2958-2970.
8. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
9. Anderson N.G., Ahmad T., Chan K., Dobson R., Bundred N.J. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 2001, 94:774-782.
10. Herbst R.S., Fukuoka M., Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat. Rev. Cancer 2004, 4:956-965.
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
12. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
13. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., Yamamoto S., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Shibata T., Sakiyama T., Yoshida T., Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:6829-6837.
14. Chu C.T., Everiss K.D., Wikstrand C.J., Batra S.K., Kung H.J., Bigner D.D. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 1997, 324(Pt. 3):855-861.
15. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
16. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 2008, 105:2070-2075.
17. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
18. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005, 2:e313.
19. Bishayee A., Beguinot L., Bishayee S. Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail. Mol. Biol. Cell 1999, 10:525-536.
20. Matuoka K., Shibata M., Yamakawa A., Takenawa T. Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries. Proc. Natl. Acad. Sci. USA 1992, 89:9015-9019.
21. Saito Y., Furukawa T., Arano Y., Fujibayashi Y., Saga T. Basic study on SH2 domain of Grb2 as a molecular probe for detection of RTK activation. Int. J. Oncol. 2010, 37:281-287.
22. Kim D., Jeon C., Kim J.H., Kim M.S., Yoon C.H., Choi I.S., Kim S.H., Bae Y.S. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp. Cell Res. 2006, 312:1277-1288.
23. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
24. Tan M., Lan K.H., Yao J., Lu C.H., Sun M., Neal C.L., Lu J., Yu D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006, 66:3764-3772.
25. Harada H., Kizaka-Kondoh S., Hiraoka M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006, 13:16-26.
26. Sorriento D., Campanile A., Santulli G., Leggiero E., Pastore L., Trimarco B., Iaccarino G. A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity. Mol. Cancer 2009, 8:97.
27. Tunnemann G., Martin R.M., Haupt S., Patsch C., Edenhofer F., Cardoso M.C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 2006, 20:1775-1784.
28. Gay B., Suarez S., Caravatti G., Furet P., Meyer T., Schoepfer J. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int. J. Cancer 1999, 83:235-241.
29. Li N., Lorinczi M., Ireton K., Elferink L.A. Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase. J. Biol. Chem. 2007, 282:16764-16775.
30. Katterle Y., Brandt B.H., Dowdy S.F., Niggemann B., Zanker K.S., Dittmar T. Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. Br. J. Cancer 2004, 90:230-235.